FOOD AND DRUG ADMINISTRATION (FDA)

Center for Biologics Evaluation and Research (CBER)
159th Meeting of the Vaccines and Related Biological Products Advisory Committee
(VRBPAC)

FDA White Oak Campus, Building 31, Great Room Salon B & C
Silver Spring, MD
March 4, 2020
AGENDA
Meeting Link:

https://collaboration.fda.gov/vrbpac030420/

March 4, 2020

Topic I: Strain Selection for the Influenza Virus Vaccines for the 2020 – 2021 Influenza Season **Topic II:** Presentation of the Laboratory of Respiratory and Special Pathogens (LRSP), Division of Bacterial, Parasitic, and Allergenic Products (DBPAP), Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER)

Note: Committee members are participating in person

Time	Presentation/Presenter
8:30am – 8:40am	Opening Remarks: Call to Order, Introduction of Committee
	Hana El Sahly, M.D.
	Chair, VRBPAC
8:40am – 8:50am	Administrative Announcements, Conflict of Interest Statement
	Kathleen Hayes, M.P.H.
	Designated Federal Officer, VRBPAC
	CBER, FDA
8:50am – 9:00am	<u>Introduction</u>
	Anissa Cheung, M.Sc.
	Regulatory Coordinator
	Division of Viral Products
	Office of Vaccines Research and Review
	CBER/FDA
9:00am – 9:05am	Question & Answers
9:05am – 9:25am	<u>U.S. Surveillance</u>
	Lisa Grohskopf, M.D., M.P.H.
	CAPT USPHS
	Associate Chief for Policy & Liaison
	Activities, Epidemiology & Prevention Branch, Influenza Division
	Centers for Disease Control and Prevention (CDC)
9:25am – 9:30am	Question & Answers

9:30am – 10:30am	Global Influenza Virus Surveillance and Characterization
	David Wentworth, Ph.D.
	Branch Chief
	Influenza Division
	Virology, Surveillance, and Diagnostic Branch
	Centers for Disease Control and Prevention (CDC)
10:30am – 10:40am	Question & Answers
10:40am – 10:50am	BREAK
10:40am – 10:50am 10:50am – 11:10am	
10:50am – 11:10am	DoD Vaccine Effectiveness Report Mark Salvalla # Ph. D. M.P.H.
	Mark Scheckelhoff, Ph.D., M.P.H.
	CDR, USPHS
	Armed Forces Health Surveillance Branch
11:10am – 11:15am	Question & Answers
11 15 11 05	
11:15am – 11:35am	Candidate Vaccine Strains & Potency Reagents
	Manju Joshi, Ph.D.
	Lead Biologist
	Division of Biological Standards & Quality
	Office of Compliance and Biologics Quality
	CBER/FDA
11:35am – 11:40am	Question & Answers
11.554111 11.404111	Question & This wers
11:40am – 12:00pm	Comments from Manufacturer Representative
	Penny L. Post, Ph.D.
	Head of Regulatory Affairs
	Sanofi Pasteur
12:00pm – 12:05pm	Question & Answers
12.00pm – 12.05pm	Question & This wers
12:05pm – 12:50pm	Lunch (45 min.)
12:50pm – 1:35pm	Open Public Hearing (45 min.)
1:35pm – 2:45pm	Committee Discouries Described to 157 (
1.55pm – 2.45pm	Committee Discussion, Recommendations, and Vote
2.45	Tonia H. I about one of Despire town and Special Dath areas (I DSD)
2:45pm	Topic II: Laboratory of Respiratory and Special Pathogens (LRSP)
	Division of Bacterial, Parasitic, and Allergenic Products (DBPAP)
	Office of Vaccines Research and Review (OVRR)
	Center for Biologics Evaluation and Research (CBER)

2:45pm – 2:50pm	Conflict of Interest Statement
	Kathleen Hayes, M.P.H.
	Designated Federal Officer, VRBPAC
	CBER, FDA
2:50pm – 3:05pm	Overview of Research/Site Visit Process, CBER
	Carolyn Wilson, Ph.D.
	Associate Director for Research
	CBER/FDA
3:05pm – 3:10pm	Question & Answers
2.10 2.25	O
3:10pm – 3:25pm	Overview of the Office of Vaccines Research and Review (OVRR) &
	Overview of the Division of Bacterial, Parasitic, and Allergenic Products
	(DBPAP)
	Jay Slater, M.D.
	Director
	Division of Bacterial, Parasitic, and Allergenic Products (DBPAP)
	Office of Vaccines Research and Review
	CBER/FDA
	CBER/I'DA
3:25pm - 3:30pm	Question & Answers
3:30pm – 3:40pm	Overview of the Laboratory of Respiratory and Special Pathogens
	Michael Schmitt, Ph.D.
	Chief
	Laboratory of Respiratory and Special Pathogens
	Division of Bacterial, Parasitic, and Allergenic Products (DBPAP)
	Office of Vaccines Research and Review
	CBER/FDA
3:40pm – 3:45pm	Question & Answers
3.40pm – 3.43pm	Question & Answers
3:45pm – 3:55pm	BREAK
3:55pm – 4:10pm	Open Public Hearing
4:10pm – 5:10pm	Closed Session
	Committee Discussion, Recommendations and Vote
5.10	A Process Minusers
5:10pm	Adjourn Meeting